Literature DB >> 11737059

MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy.

T R Orchard1, A Dhar, J D Simmons, R Vaughan, K I Welsh, D P Jewell.   

Abstract

MHC class I chain gene A (MICA) is a non-classical Class I gene which is expressed on the surface of epithelia without beta 2-microglobulin. The gene is found in the major histocompatibility complex (MHC) in tight linkage disequilibrium with human leucocyte antigen-B (HLA-B). Its precise function is unknown, but it interacts with gamma delta T cells of the intestinal immune system. This region of the MHC has been implicated in inflammatory bowel disease (IBD) pathogenesis by recent association mapping studies and this study was performed to examine the prevalence of MICA gene polymorphisms in IBD, in particular in type 2 peripheral arthropathy (PeA), which also has a strong HLA-B association. An assessment of the prevalence of MICA polymorphisms in IBD was made. Blood from 50 ulcerative colitis (UC) and 50 Crohn's disease controls was taken and MICA status determined using allele-specific PCR for 16 known alleles of MICA. A further 91 UC patients were recruited to confirm the results of this stage, and then the polymorphisms were studied in 52 type 1 and 45 type 2 PeA patients. The MICA status of these groups was compared with 118 blood and organ donor controls with appropriate correction for multiple comparisons. UC overall was associated with possession of MICA*007 in 32% compared to 11% of controls (P(c) = 0.017). This association was confirmed in a second cohort of 91 patients (23% versus 11%, P = 0.02). These were independent of HLA class I status. Type 2 IBD PeA was associated with MICA*008 in 98% compared to 73% of controls (P = 0.0001). MICA*007 is associated with susceptibility to UC in our population and MICA*008 with type 2 IBD PeA. Further work is now required to assess the distribution and expression of MICA throughout the gut in health and disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11737059      PMCID: PMC1906229          DOI: 10.1046/j.1365-2249.2001.01662.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27).

Authors:  E G Mallas; P Mackintosh; P Asquith; W T Cooke
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

2.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP).

Authors:  M Bunce; C M O'Neill; M C Barnardo; P Krausa; M J Browning; P J Morris; K I Welsh
Journal:  Tissue Antigens       Date:  1995-11

3.  Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy.

Authors:  C Cuvelier; H Mielants; M De Vos; E Veys; H Roels
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

4.  Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease.

Authors:  T R Orchard; S Thiyagaraja; K I Welsh; B P Wordsworth; J S Hill Gaston; D P Jewell
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

5.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

Authors:  J Satsangi; K I Welsh; M Bunce; C Julier; J M Farrant; J I Bell; D P Jewell
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

6.  Linkage of inflammatory bowel disease to human chromosome 6p.

Authors:  J Hampe; S H Shaw; R Saiz; N Leysens; A Lantermann; S Mascheretti; N J Lynch; A J MacPherson; S Bridger; S van Deventer; P Stokkers; P Morin; M M Mirza; A Forbes; J E Lennard-Jones; C G Mathew; M E Curran; S Schreiber
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

7.  Nucleotide sequence of the human MHC class I MICA gene.

Authors:  S Bahram; N Mizuki; H Inoko; T Spies
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

8.  Allelic repertoire of the human MHC class I MICA gene.

Authors:  N Fodil; L Laloux; V Wanner; P Pellet; G Hauptmann; N Mizuki; H Inoko; T Spies; I Theodorou; S Bahram
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

9.  Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease.

Authors:  W S Selby; G Janossy; D Y Mason; D P Jewell
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  A second lineage of mammalian major histocompatibility complex class I genes.

Authors:  S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

View more
  17 in total

Review 1.  In vivo immunogenetics: from MIC to RAET1 loci.

Authors:  Mirjana Radosavljevic; Seiamak Bahram
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

Review 2.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

Review 4.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 5.  Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region.

Authors:  Manuel Muro; Ruth López-Hernández; Anna Mrowiec
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

6.  NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8+ T cell migration.

Authors:  Kasper Vadstrup; Elisabeth Douglas Galsgaard; Helle Jensen; Lewis L Lanier; James C Ryan; Shih-Yu Chen; Garry P Nolan; Marianne Kajbæk Vester-Andersen; Julie Steen Pedersen; Jens Gerwien; Teis Jensen; Flemming Bendtsen
Journal:  Exp Mol Pathol       Date:  2017-07-03       Impact factor: 3.362

7.  MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset.

Authors:  A Martinez-Chamorro; A Moreno; M Gómez-García; M J Cabello; J Martin; M Á Lopez-Nevot
Journal:  Clin Exp Immunol       Date:  2016-04-05       Impact factor: 4.330

8.  MICA, a gene contributing strong susceptibility to ankylosing spondylitis.

Authors:  Xiaodong Zhou; Jiucun Wang; Hejian Zou; Michael M Ward; Michael H Weisman; Maribel G Espitia; Xiangjun Xiao; Effie Petersdorf; Emmanuel Mignot; Javier Martin; Lianne S Gensler; Paul Scheet; John D Reveille
Journal:  Ann Rheum Dis       Date:  2013-06-01       Impact factor: 19.103

Review 9.  Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease?

Authors:  Elisabetta Colombo; Anna Latiano; Orazio Palmieri; Fabrizio Bossa; Angelo Andriulli; Vito Annese
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

10.  In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer.

Authors:  Stéphanie Schrambach; Marc Ardizzone; Vincent Leymarie; Jean Sibilia; Seiamak Bahram
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.